Lynparza shows PFS benefit of 3.6 months in pancreatic cancer

AstraZeneca’s Lynparza olaparib has hit the minimum three-month benefit that oncologists were hoping to see in pancreatic cancer. Data presented Sunday at ASCO position the PARP inhibitor to become the first targeted agent to treat a biomarker-defined subgroup of patients with metastatic pancreatic cancer, if approved.

The detailed data, from the Phase III POLO trial of Lynparza as first-line maintenance therapy of germline BRCA-mutated metastatic pancreatic cancer, showed that the drug led to an improvement in progression-free survival of 3.6 months over placebo. The data were also published in The New England Journal of Medicine...